College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University, Jeonju, 561-756, Republic of Korea.
Vet Res. 2010 Sep-Oct;41(5):59. doi: 10.1051/vetres/2010031. Epub 2010 May 21.
To construct a novel live vaccine candidate for fowl typhoid (FT) caused by Salmonella Gallinarum (SG), the lon and cpxR genes that are related to host-pathogen interaction were deleted from a wild type SG using the allelic exchange method. The mutants were grown normally, as was the wild type. The biochemical properties of the mutants remained very similar to those of the wild-type, while JOL914 (Deltalon) and JOL916 (DeltalonDeltacpxR) were mucoid. Extracellular polysaccharide increased 30.6-, 1.3-, and 46.2-fold in JOL914, JOL915 (DeltacpxR), and JOL916, respectively. Dot-blot analysis demonstrated significant increases of FimA expression at 6.77-, 2.33-, and 3.90-fold for JOL914, JOL915, and JOL916, respectively. Internalizations of JOL914, JOL915, and JOL916, in chicken abdominal macrophages, were increased at 4.65-, 0.50-, and 2.72-fold, respectively. Virulences of JOL914, JOL915 and JOL916, analyzed by LD50 using 1-week-old chickens, were attenuated approximately at 10(1)-, 10(1)-, and >10(3)-fold, respectively. The oral inoculations of 2x10(7) cfu of the wild type, JOL914, JOL915 and JOL916 caused 55.6, 16.7, 22.2, and 0.0% mortality, respectively. Significantly moderate gross lesions of the liver and spleen were observed in the JOL916 group compared to the other groups. An induced immune response and significant peripheral mononuclear proliferation reaction were observed in the JOL916 group. At the protection against the wild type challenge, JOL916 offered 100% protection. Thus, the results of this study suggest that JOL916 among the mutants studied represented the safest and most effective live vaccine candidate against FT.
为了构建一种新型的鸡伤寒(FT)活疫苗候选株,本研究使用基因敲除的方法从野生型鸡伤寒沙门氏菌中敲除了与宿主-病原体相互作用相关的 lon 和 cpxR 基因。突变株的生长情况与野生型相同,生化特性也非常相似,而 JOL914(Δ lon )和 JOL916(Δ lon Δ cpxR )则呈现黏液型。JOL914、JOL915(Δ cpxR )和 JOL916 的胞外多糖分别增加了 30.6 倍、1.3 倍和 46.2 倍。斑点印迹分析表明,JOL914、JOL915 和 JOL916 的 FimA 表达水平分别增加了 6.77 倍、2.33 倍和 3.90 倍。在鸡腹腔巨噬细胞中,JOL914、JOL915 和 JOL916 的内化分别增加了 4.65 倍、0.50 倍和 2.72 倍。通过对 1 日龄鸡进行 LD50 分析,JOL914、JOL915 和 JOL916 的毒力分别减弱了约 10 1 倍、10 1 倍和 >10 3 倍。口服 2x10 7 个 CFU 的野生型、JOL914、JOL915 和 JOL916 ,分别导致 55.6%、16.7%、22.2%和 0.0%的死亡率。与其他组相比,JOL916 组鸡的肝脏和脾脏病变明显中度严重。JOL916 组诱导了免疫应答和显著的外周单核细胞增殖反应。在抵抗野生型攻毒方面,JOL916 提供了 100%的保护。因此,本研究结果表明,在所研究的突变株中,JOL916 是一种最安全、最有效的鸡伤寒活疫苗候选株。